Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...

Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics impacting IBD treatment options. The gastroenterology biosimilar landscape is ...

Explore the latest developments in the US biosimilar market, highlighting key approvals, challenges, and future trends ...

The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of the biosimilar market into ophthalmology is helping to redefine treatment ...

A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab ...